Revised SPCs: Atrolak (quetiapine fumarate) XL prolonged-release tablets - all strengths
SPC updated with warnings of increased risk of self-harm & suicide in patients 25- 64 yrs and increased risk of death in patients >65 years with Parkinson's disease/parkinsonism. Stroke added as an adverse effect of treatment (of unknown frequency).
Source:
electronic Medicines compendium